



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 211/94, 295/22, A61K 31/445	A1	(11) International Publication Number: WO 95/17385 (43) International Publication Date: 29 June 1995 (29.06.95)
(21) International Application Number: PCT/US94/14850 (22) International Filing Date: 22 December 1994 (22.12.94) (30) Priority Data: 173,382 23 December 1993 (23.12.93) US (71) Applicant: ORTHO PHARMACEUTICAL CORPORATION [US/US]; U.S. Route 202, Raritan, NJ 08859 (US). (72) Inventors: REITZ, Allen, B.; 109 Greenbriar Road, Lansdale, PA 19446 (US). McDONNELL, Mark, E.; 1280 Sumneytown Pike, Lansdale, PA 19446 (US). (74) Agents: CIAMPORCERO, Audley, A., Jr. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: N-OXIDES OF 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES AS ANTIPSYCHOTIC DRUGS		
<div style="text-align: center;"> </div> <div style="text-align: right;">(I)</div>		
(57) Abstract Compounds of general formula (I) are disclosed as novel antipsychotic agents.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

N-OXIDES OF 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES AS ANTIPSYCHOTIC DRUGS

5 BACKGROUND OF THE INVENTION


Antipsychotic drugs are known to alleviate the symptoms of mental illnesses such as schizophrenia. Examples of such drugs include phenothiazine derivatives such as promazine, chlorpromazine,
1 0 fluphenazine, thioridazine and promethazine, thioxanthenes such as chlorprothixene, butyrophenones such as haloperidol and clozapine. While these agents may be effective in treating schizophrenia, virtually all except clozapine produce extrapyramidal side effects, such as facial tics or tardive dyskinesia. Since antipsychotics may be administered for years or decades
1 5 to a patient, such pronounced side effects may complicate recovery and further isolate the individual from society.

Compounds having some structural similarity to those of the present invention are described in EPO application 88,309,581.2, U. S. Patent Nos.
2 0 4,772,604; 4,782,061; 4,362,738; 3,988,371; 4,666,924; 4,931,443; and 4,992,441. Other somewhat similar compounds are disclosed in *J. Clin. Chem. Clin. Biochem.* **1988**, 26, 105 and *J. Med. Chem.*, **1991**, 34, 2133.

The present invention describes novel compounds that display activity
2 5 in mammals suggestive of antipsychotic activity in man. The receptor binding profile shows only weak affinity for the dopamine-2 receptor, which may be an indication that the N-oxide functionality is being metabolically reduced *in vivo* to the corresponding piperazines and piperidines. Such piperazines and piperdines are disclosed and claimed in WO 9304682, 18
3 0 Mar 1993. See also application Serial No. 944,006, filed September 11, 1992.

SUMMARY OF THE INVENTION


3 5 Compounds of the general formula I:



wherein Ar, W, A, B, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and n, as defined hereinafter, are potent antipsychotic agents useful in the treatment of psychotic conditions such as schizophrenia in animals and humans. The compounds of the present invention may also be useful in the treatment of other disorders of the central nervous system such as anxiety and aggression.

10 DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compounds represented by the general formula I:



wherein

A is N, CH, or N⁺-O⁻.

B is N, or N⁺-O⁻; with the proviso that when A is N or CH, B must be N⁺-O⁻; and when A is N⁺-O⁻, B must be N.

W is C or SO. More preferably, W is C.

R¹ and R² are independently selected from any of H or C₁-C₄ alkyl. More preferably, R¹ and R² are each H.

n = 0-4 and more preferably n=0.

R³ and R⁴ are either both H, or one of them is H and the other is C₁-C₄ alkyl or hydroxyl, or both are taken together as oxygen to form a carbonyl group with the attached carbon atom; except when n = 0. More preferably, R³ and R⁴ are each H.

R⁵ and R⁶ are independently selected from any one of H, C₁-C₈ alkyl, C₁-C₈ alkoxy, nitro, halogen, haloalkyl, C₁-C₈ alkylthio, amino, C₁-C₈ mono- or dialkyl amino, or C₁-C₈ alkylamido. Preferably, R⁵ and R⁶ are independently selected from any one of H, C₁-C₈ alkyl, C₁-C₈ alkoxy, nitro, amino, or C₁-C₈ alkylamido and most preferably R⁵ and R⁶ are each H.

R⁷ is O or S where W is C; and R⁷ is O where W is SO. More preferably, R⁷ is O.



R⁸ and R⁹ are independently selected from any one of H, C₁-C₈ alkyl, phenyl, substituted phenyl, aralkyl wherein the alkyl portion is C₁-C₈, alkoxycarbonylamido, acyl, C₃ to C₁₀ cycloalkyl; or -NR⁸R⁹ may be taken together to form a ring having 4-10 ring atoms, preferably 4-8 ring atoms, which ring may be saturated or unsaturated, preferably saturated, substituted or unsubstituted, and may contain up to one more hetero atoms in addition to the ring N, such as S, O or N within the ring; more preferably, the additional hetero atoms are N or O; even more preferably, the additional hetero atom is O; and most preferably, there are no additional hetero atoms; or optionally the -NR⁸R⁹ ring may be combined with a 2-4 membered carbon moiety to form a fused bicyclic ring, which may be saturated or unsaturated, and unsubstituted or substituted; or optionally the NR⁸R⁹ ring may be combined with a four membered moiety containing at least two carbon atoms and up to two hetero atoms selected from S or O, but preferably selected from O, to form a spirocycle ring system which may be saturated or unsaturated, preferably saturated, substituted or unsubstituted. More preferably, the 2-4 membered carbon moiety is combined with a -NR⁸R⁹ ring which contains 5-7 ring atoms with the N being the only hetero atom in the ring, thereby forming a fused ring system. Most preferably, the -NR⁸R⁹ ring is saturated prior to being fused with the 2-4 membered carbon moiety. Most preferably, R⁸ and R⁹ are taken together with the N to form a 6 membered fully saturated ring which may be substituted or unsubstituted.

When -NR⁸R⁹ are taken together to form a ring, a fused ring system or a spirocycle ring system, such rings may be independently substituted with any of C₁-C₈ alkyl, C₁-C₈ alkoxy, phenyl, substituted phenyl (wherein phenyl may be substituted with any of the substituents listed hereinafter for R¹⁰ or R¹¹ substituted phenyl), hydroxy, aralkyl such as benzyl, wherein the alkyl portion is C₁-C₈, oxo or thioxo. The preferred substituents for the


-NR⁸R⁹ ring are C₁-C₈ alkyl, hydroxy or oxo. The preferred substituents for the fused ring system are C₁-C₄ alkoxy. The spirocycle ring system is preferably unsubstituted and saturated.

- 5 Examples of preferred ring systems wherein -NR⁸R⁹ are taken together to form a ring having 4-10 ring atoms include pyrrolidine, piperidine, hexahydroazepine, octahydroazocine, oxazine and 2,6-dimethylpiperidine.

10 Examples of preferred fused ring systems for -NR⁸R⁹ are represented by formulas III and IV:



15 As used herein for the definition of -NR⁸R⁹, a spiro ring system is a 2 ring system, the union of which is formed by a single atom which is the only common member of the two rings. A particularly preferred spirocycle ring is represented by the formula V:




20

Ar is aryl such as phenyl or naphthyl, heteroaryl or substituted aryl wherein aryl may be independently substituted with one or more of C₁-C₈ alkyl, cycloalkyl, hydroxyalkyl, C₁-C₈ alkoxy, aryloxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, C₁-C₈ alkylthio, halogen, nitro, C₁-C₈ haloalkyl, amino or C₁-C₈ mono- or di-alkylamino. Alkoxy, such as i-propoxy or methoxy are presently the preferred substituents. As a halogen, the substitution is preferably fluorine, chlorine, or bromine. Optionally,

present hydroxyl or hydroxyalkyl groups may be esterified or etherified. Examples of suitable heteroaryl rings are pyrimidinyl, pyridinyl, pyridazinyl, pyrazinyl, imidazyl, pyrrole, furan, thiophene, triazolyl, and thiazolyl. The preferred heteroaryl rings are pyrimidinyl and pyridinyl. More preferably, Ar is substituted phenyl.

Ar may also be a fused ring system of the formula II:



10

wherein B together with the 2 carbon atoms of the phenyl group forms an entirely or partly unsaturated cyclic group having 5-7 ring atoms and within the ring 0-3 hetero atoms from the group O, S and N may be present with the proviso that the sum of the number of oxygen atoms and sulfur atoms is at most 2, and that the nitrogen atoms in the ring may be substituted with R¹² selected from any one of H, C₁-C₈ alkyl, hydroxyalkyl or C₁-C₈ acyl;

R¹⁰ and R¹¹ may be independently selected from any one of alkyl, cycloalkyl, phenyl, substituted phenyl or heteroaryl, hydroxyalkyl, alkoxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, mono- or dialkylamino, mono- or diarylamino, hydroxyl, amino, alkyl-, alkoxy-, amino-, or mono- or dialkylamino-carbonyl, nitro, cyano, halogen, trifluoromethyl, trifluoromethoxy, amino or mono- or dialkylaminosulfonyl. R¹⁰ may also be an oxo or thioxo group. Variable m has the value 0-3 and p has the value 0-2. More preferably, R¹⁰ and R¹¹ are selected from any of alkoxy, halogen or cyano.

More preferred values for the moiety of formula II are: B forms together with the two carbon atoms of the phenyl group an entirely or partly unsaturated ring consisting of 5 atoms, which ring comprises at least one oxygen atom. R¹⁰ and R¹¹ are selected from any of alkyl, alkoxy, hydroxyl, nitro, cyano, halogen, or trifluoromethyl. R¹⁰ and R¹¹ are more preferably selected from any of alkoxy, halogen or cyano. R¹⁰ is preferably in the meta

or ortho position in relation to the piperazine/piperidine group. Variables m and p have the value 0-2. A particular preferred subgenus of such compounds are those wherein m and p each have a value of 0.

- 5 When R¹⁰ or R¹¹ comprises an alkyl group, it is preferably a straight or branched alkyl group having 1-5 carbon atoms. As a cycloalkyl group, the groups R¹⁰ or R¹¹ comprise a ring system having 3-7 ring atoms and not more than 10 carbon atoms including any substituents as a whole. When R¹⁰ or R¹¹ is a hydroxyalkyl group such a group preferably comprises 1-5 carbon atoms. As a halogen atom, R¹⁰ or R¹¹ preferably is fluorine, chlorine or bromine. Optionally present hydroxyl or hydroxyalkyl groups may be esterified or etherified.
- 10

- When R¹⁰ or R¹¹ is substituted phenyl it may be substituted with one or more of C₁-C₈ alkyl, C₁-C₈ alkoxy, halogen, trifluoromethyl, C₁-C₈ alkylthio, dialkylamino (wherein each alkyl is C₁-C₈), C₁-C₈ alkylamino, nitro or mono- or dialkylamino sulfonyl (wherein each alkyl is C₁-C₈).
- 15




- As used herein, unless otherwise noted alkyl and alkoxy whether used alone or part of a substituent group, include straight and branched chains. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, 2-methyl-3-butyl, 1-methylbutyl, 2-methylbutyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl. Alkoxy radicals are oxygen ethers formed from the previously described straight or branched chain alkyl groups. Of course, if the alkyl or alkoxy substituent is branched there must be at least 3 carbon atoms.
- 20
- 25

- The term "aryl" as used herein alone or in combination with other terms indicates aromatic hydrocarbon groups such as phenyl or naphthyl. The term "heteroaryl" means aromatic hydrocarbon groups containing 1 or 2 hetero atoms selected from any of S, O or N. The term "aralkyl" means a C₁-C₈ alkyl group substituted with an aryl group. The term acyl, unless otherwise specified herein, means a benzoyl or a C₁-C₈ alkanoyl group, which can be optionally substituted. With reference to substituents, the term independently means that when more than one of such substituent is possible such substituents may be the same or different from each other.
- 30
- 35

Compounds according to this invention have a 1,2-, 1,3- or 1,4-relationship of the W substituent with the -C(R³)(R⁴)- group on the W-bearing

phenyl ring. Preferred compounds have a 1,2- or 1,3- relationship of these two groups. The R^5 and R^6 substituents may be located in any of the other unsubstituted ring positions.

- 5 Particularly preferred subgenres of compounds of the formula I are those of the formula (Ia-Ic):



- 15 wherein R^8 and R^9 are as defined above and R^{12} and R^{13} are as defined as substituents for Ar in formula I. Preferably, R^8 and R^9 are taken together with the N to form a saturated ring having 5-8 ring atoms and one of R^{12} and R^{13} is C_1 - C_8 alkoxy and the other is H. The most preferred C_1 - C_8 alkoxy groups are i-propoxy or methoxy.

20

Examples of particularly preferred compounds include:

1-[3-[[4-[2-(1-Methylethoxy)phenyl]-4-oxide-1-piperazinyl]methyl]-benzoyl]piperidine;

25

1-[3-[[4-[2-(1-Methylethoxy)phenyl]-1-piperazinyl-1-oxide]methyl]-benzoyl]piperidine; and

1-[3-[[4-[2-(1-Methylethoxy)phenyl]-1-piperidiny]-1-oxide]methyl]-benzoyl]piperidine monohydrochloride.


5 The invention definition of formula I includes racemates and individual isomers, e.g. as caused by the presence of a stereogenic carbon such as when a substituent would be 2-butyl. Also within the scope of the invention are compounds of the invention in the form of hydrates and other solvate forms.

10

Representative salts of the compounds of formula I which may be used include those made with acids such as hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, maleic, fumaric, malic, tartaric, citric,
15 benzoic, cinnamic, mandelic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclohexanesulfamic, salicyclic, *p*-aminosalicyclic, 2-phenoxybenzoic, 2-acetoxybenzoic or a salt made with saccharin. Such salts can be made by reacting the free base of formula I with the acid and recovering the salt.

20

The compounds of formula I may be prepared according to Reaction Scheme 1.

Reaction Scheme 1


- 5 As shown, oxidant refers to any reagent or reagent mixture capable of transferring an oxygen to a nitrogen atom to convert it to the N-oxide functionality. Examples of such reagents are peracids, such as m-chloroperoxybenzoic acid and peracetic acid. Suitable solvents would include halogenated solvents such as methylene chloride and chloroform.
- 10 Another reagent capable of effecting this transformation is ruthenium on carbon (5 %) in the presence of sodium acetate, acetic acid, and peracetic acid. Occasionally, the products can be obtained immediately from the reaction without the need for chromatographic purification. However, when
- 15 the two different singly oxidized compounds (A = N⁺-O⁻, B = N and B = N, A = N⁺-O⁻) can be separated from each other by chromatographic methods such as by flash column chromatography on silica gel.

20 The requisite piperazines and piperidines of formula II described herein and in Examples 1-3 are prepared as described in WO 9304682 (18 Mar 1993), being a CIP of WO 9304684 (18 Mar 1993). More specifically,

the requisite piperazines and piperidines of formula II may be prepared as described in Reaction Schemes 2-8.

The compounds of formula II may be prepared according to Reaction
5 Scheme 2:

Reaction Scheme 2



10


As shown, the 1,2-, 1,3-, and 1,4-disubstituted benzamides or
sulfonamides may be prepared by a sequential reaction with the appropriate
haloalkyl benzoyl halide or haloalkyl benzenesulfonyl halide (VI). The first
condensation with the requisite amine is conducted in a non-protic solvent
such as tetrahydrofuran (THF) with cooling (e.g. in the range -78°C to 5°C),
being careful not to let the solution exotherm so as to avoid reaction of the
haloalkyl functionality. The base present in the reaction (for the removal of
the HX formed) is typically a tertiary amine such as triethylamine or di-
isopropylethylamine, or it could be a molar excess (at least) of the amine
reactant (e.g. R⁸R⁹NH). The intermediate haloalkyl benzamide thus formed
could be then taken on directly to the product by reaction with the aryl
piperazine or aryl piperidine (VII), or it could be isolated after an extractive
workup and/or chromatography. If the intermediate was carried on in situ to
the product (VIII) in THF, heating (30°C-67°C) is generally required for
complete reaction. If the intermediate is isolated and then reacted
separately with the aryl piperazine or aryl piperidine, the optimal solvents
are dipolar aprotic solvents such as dimethylformamide (DMF) or N-methyl-
2-pyrrolidinone. The base used in this latter step could be a tertiary amine
or potassium or sodium carbonate. Using the two-step method (i.e. isolation
of the intermediate), the product could in some cases be obtained pure after
recrystallization as a salt without resort to chromatography.

1,2- and 1,3-Halomethylbenzoyl halides used when $m=1$ in Reaction Scheme 2 are commercially available from Fluka, Carbolabs or Pfaltz and Bauer, or could be prepared by literature methods or modifications thereof. (See e.g.: Ger. Offen. 2,835,440, 28 Feb. 1980; and J. Johnson and I.

5 Pattison *J. Hetero. Chem.* **1986**, 23, 249). Halomethyl benzoyl halides bearing substituents have also been described in the literature, such as in the methoxy-substituted case cited in R. Quelet *et al. Bull. Soc. Chem., France* **1969**, 1698. The final products are typically chromatographed to achieve purity, and then converted to an acceptable salt form.


10 The 1,3- or 1,4-disubstituted analogs may be prepared in the same manner as the derivatives shown above. There are alternative methods for the preparation of compounds of this type. For example, they may be synthesized by a palladium-mediated coupling of a bromoaryl derivative
 15 with carbon monoxide and piperidine (*J. Org. Chem.* **1974**, 39, 3327) as shown in Reaction Scheme 3 for a 1,4-disubstituted case.

Reaction Scheme 3




20 The preparation of the sulfonamide analogues ($W = \text{SO}$, $\text{R}^7 = \text{O}$, and $n = 0$ in II) require preparation of the necessary halomethyl sulfonyl halide by halogenation of the appropriate toluenesulfonyl halides on the benzylic
 25 methyl position with *N*-bromosuccinimide mediated by benzoyl peroxide. The halomethyl sulfonyl halides were used in generally the same manner as for the benzoyl halide case (e.g. see Reaction Scheme 3).

30 Many aryl piperazines are commercially available from Aldrich Chemical Company or may be prepared by standard methods known in the art (for example see G. E. Martin *et al. J. Med. Chem.* **1989**, 32, 1052). These piperazines (VII, $\text{A}=\text{N}$) may be obtained according to the following Reaction Scheme 4 where Ar is as described in connection with formula II and Z is a leaving group such as halo (e.g. chloro):


Reaction Scheme 4

- 5 In carrying out Reaction Scheme 4, compound XII is heated with an aniline or an aromatic heterocyclic primary amine XI at about 50 to 120°C in a solvent such as n-butanol with recovery of the piperazine VII (A=N).

- 10 Piperazines of formula VII (A=N) where Ar is a formula II moiety are described as formula (2) in U.S. Patent 4,782,061 published earlier as EPO 185,429 and EPO 190,472 on June 15, 1986 and August 13, 1986, respectively, which documents are hereby incorporated by reference. Other piperazines of formula VII (A=N) where Ar is a formula II moiety are described as formula 29 in EPO 138,280 published April 24, 1985 which is
- 15 incorporated by reference. In addition, some of the piperazines of formula VII can be prepared by the method of ten Hoeve *et al.* (*J. Org. Chem.* 1993, 58, 5101), involving the displacement of a methoxy aromatic by piperazine or a piperazine derivative.
- 20 Other piperazines may be prepared by the method of I. van Wijngaarden *et al.* (*J. Med. Chem.* 1988, 31, 1934). Other piperidines may be prepared by the method shown in Reaction Scheme 5.

Reaction Scheme 5

5 Other piperazine may be synthesized as shown in Reaction Scheme 6.


Reaction Scheme 6

10

The piperazines required to prepare 2-fluoropiperazinyl compounds may be prepared by nucleophilic displacement of 1,2-difluorobenzene with the requisite piperazine such as in reaction of 2,5-dimethylpiperazine with 1,2-difluorobenzene in the presence of sodium amide.

15

Alternatively, certain other compounds useful in making the compounds of the invention can be prepared by the method shown in Reaction Scheme 7.


Reaction Scheme 7

- 5 Aryl piperazines **VII** (A=N) can be condensed with compounds **XXII** in which Y represents a leaving group suitable for a displacement reaction (e.g. halogen, *p*-toluenesulfonate, trifluoromethanesulfonate) to give compounds **XXIII**. This displacement reaction is typically carried out in a dipolar aprotic solvent such as DMSO or DMF, using sodium carbonate, potassium
- 10 carbonate, or a tertiary amine [e.g. triethylamine or di(isopropyl)ethylamine] as the base, generally with heating (30-80°C for 2h to 4d). The resulting ketone (**XXIII**) can be converted to amide **XXIV** by the aminocarbonylation reaction described for Reaction Scheme 3. Reduction of the carbonyl group of **XXIV** by the use of sodium borohydride in alcoholic solvents (EtOH,
- 15 iPrOH) at room temperature (2-30h) can give alcohol **XXV**. Further reduction of **XXV** by the method of catalytic hydrogenation (H₂, palladium/carbon) in alcoholic solvents (e.g. EtOH), in the presence of added mineral acid (e.g. HCl) to facilitate the reaction, can afford compounds **XXVI**.

Compounds of formula II may also be prepared by the chemistry shown in Reaction Scheme 8.

REACTION SCHEME 8

5



Carbonyl compound **XXVII** is reacted with compounds **VII** in a reductive amination reaction to give compounds **XXVIII**. This reaction can be carried out using sodium borohydride in titanium isopropoxide. It can also be conducted by forming an imine from **VII** and **XXVII** and then reducing it catalytically with hydrogen in the presence of a noble metal catalyst (e.g. palladium or platinum). Hydrolysis of the nitrile functionality of **XXVIII** to give **XXIX** is carried out in the presence of sodium hydroxide or potassium hydroxide, usually at reflux in an alcoholic solvent. Compound **XXIX** is then combined with R⁸R⁹NH to form amide **XXX**, using one of the standard reactions to accomplish this transformation such as the use of dicyclohexylcarbodiimide or carbonyl diimidazole.

The antipsychotic activity of the compounds of the invention may be determined by the Block of Conditioned Avoidance Responding (Rat) test (CAR), references being Cook, L. and E. Weidley in *Ann. N.Y. Acad. Sci.*, 1957, 6, 740-752, and Davidson, A.B. and E. Weidley in *Life Sci.*, 1976, 18, 1279-1284. This test was performed for compounds disclosed in this invention, and the data are listed in Table 1. A reading of -20% in the CAR test was generally taken to represent a minimum value for a compound to be designated as active at a given dose. In addition, the affinity of the

compounds for several receptors found in the central nervous system was evaluated; the affinity for the D-2 (dopamine-2) receptors is also listed in Table 1. As modulation of this receptor is generally recognized to be beneficial in the treatment of schizophrenia (G. P. Reynolds *Trends Pharmacol. Sci.* **1992**, *13*, 116), affinity for this receptor indicates potential utility for the compounds. A D-2 affinity of 1000 nM or less has been taken as predictive of antipsychotic activity.

Block of Conditioned Avoidance Responding (Rat)

1 0

Apparatus: Rat operant chambers, housed within sound attenuated booths, both from Capden Instruments Ltd., were used in this test. The test chamber (8" H x 90-3/8" W x 9" D) is constructed of aluminum and plexiglass with floor grid bars of stainless-steel (1/8" O.D.) spaced 9/16" apart. A stainless-steel operation level 1-1/2" wide projects 3/4" into the chamber and is positioned 2-2/8" above the grid floor. The shock stimulus is delivered via the grid floor by a Coulbourn Instruments solid state module. The parameters of the test and the collection of data are controlled automatically.

2 0

Training: Male, Fischer 344 rats obtained from Charles River (Kingston, NY) weighing more than 200 g, are individually housed with chow and water provided ad libitum. The rats are trained for two weeks to approach criterion levels in the avoidance test (90% avoidance rate). One-hour training sessions are run at about the same time each day for four or five days a week. The training session consists of 120 trials, with the conditioned stimuli presented every 30 sec. A trial begins with presentation of the conditioned stimuli (a light and a tone). If the rat responds by depressing the operant lever during the 15-second presentation of the conditioned stimuli, the trial is terminated and the animal is credited with a CAR. Failure to respond during the conditioned stimuli causes the presentation of the unconditioned stimulus (UCS), a 0.7 mA shock which is accompanied by a light and tone for five seconds. If the rat depressed the lever within the ten-second period, the shock and trial are terminated and an escape response recorded. If the rat fails to depress the lever during the UCS (shock), the trial is terminated after ten seconds of shock and the absence of a response is scored as a failure to escape. Intertrial lever presses have no effect. If a rat performs at the 90% CAR level for two weeks, it is then run twice a week on the test schedule (see below) until baseline performance stabilized. Before any

drug is administered, two weeks of CAR at a rate of 90% or better is required.

- 5 The percent change in CAR on the drug treatment day compared to vehicle pretreatment day is the key measure. The percent change (% change) in CAR is determined using the following formula:

$$\% \text{ change CAR} = ((\% \text{ CAR for Day 2} / \% \text{ CAR for Day 1}) \times 100) - 100$$

- 10 A negative number indicates a blockade of CAR, whereas a positive number would indicate increased CAR. The test results are reported as the mean % change for the group of rats. Failure to escape, a measure of the general sedative potential of the compound, was calculated for each animal as follows:

15

$$\% \text{ Failures} = \# \text{ of Failures to Escape} / \# \text{ of trials}$$

- 20 The % failures, viz., loss of escape, is also reported as a group mean. Failures to escape are monitored closely and a session is terminated if ten failures occurred. ED₅₀ values and 95% confidence limits are calculated using linear regression analysis. The results of the CAR tests are shown in Table I.

- 25 In the Table and formulas therein, OiPr is isopropoxy, Me is methyl, and NT is not tested in that particular test. The escape loss numbers are shown at CAR 15 mg/kg ip.

Receptor Binding Assay

- 30 The dopamine D₂ binding activity of compounds was determined using a P₂ fraction (synaptosomal membranes) prepared from male, Wistar rats. The D₂ assay employed a P₂ fraction from the striatum, the ligand ³H-spiroperone at a concentration of 0.05 nM, and 1 mM haloperidol as a blank determinant. Incubation was in 3 mM potassium phosphate buffer for 45 min
- 35 at 37°C. Under these conditions, specific binding constituted 75% of total binding, and the K_i values for some known drugs were: 0.37 nM for haloperidol and 82 nM for clozapine.

The data from this assay were analyzed by calculating the percent inhibition of the binding of the tritiated ligands by given concentrations of the test compound. K_i values, where given, were obtained from the logit analysis of concentration-inhibition curves.

5

To prepare the pharmaceutical compositions of this invention, one or more compounds or salts thereof of the invention, as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, 1 5 alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. 2 5 Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will preferably contain per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, from about 50 to about 100 mg of the active ingredient, although other unit dosages 3 0 may be employed.

In therapeutic use as an antipsychotic agent in mammals, the compounds of this invention may be administered in an amount of from about 0.5 to 5 mg/kg per day, and more preferably 1-3 mg/kg per day. The dosages, however may be varied depending upon the requirements of the patient, the severity of the condition being treated and the compound being employed. Determination of optimum dosages for a particular situation is within the skill of the art. 3 5

The following Examples illustrate the present invention, but are not deemed to be limiting. Examples 1-3 describe the preparation of specific compounds listed in the Table which follow the Examples.

5

EXAMPLE 1

1-[3-[[4-[2-(1-Methylethoxy)phenyl]-4-oxide-1-piperazinyl]methyl]benzoyl]piperidine 1.7Hydrate (Compound 1)

10 1-[3-[[4-[2-(1-Methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]-piperidine (15 g, 35.6 mmol) was treated with m-chloroperoxybenzoic acid (6.15 g, 35.6 mmol) dissolved in chloroform (100 mL). This solution was allowed to stir overnight, and the solvent was then removed. The residue was purified on a silica gel column (CHCl₃/MeOH; 100:0 to 90:10). The first component isolated consisted of unreacted starting material (9.8 g). The
15 second component isolated (380 mg) was recrystallized from methylene chloride/ether, and was identified to be the title compound by analysis of the H-1 NMR spectrum (400-MHz, CD₃OD) and mass spectrum as a white powder, mp 98-101°C. The compound was labile to prolonged heating in methanol, and was kept in the refrigerator. ¹H NMR (CD₃OD, 250 MHz) δ
20 8.4 (d, 1H), 7.4 (m, 4H), 7.3 and 7.2 (both d, 1H each), 7.1 (t, 1H), 4.9 (m, 3H), 3.7 (d, 4H), 3.4 (s, 2H), 3.15 (t, 2H), 2.8 and 2.9 (both d, 2H each), 1.7 (m, 4H), 1.5 (d, 6H).

Elemental Analysis: Calculated for C₂₆H₃₅N₃O₃•1.7H₂O: C, 66.71; H, 8.21; N, 8.98; H₂O, 6.54. Found: C, 66.90; H, 7.97; N, 8.62; H₂O, 6.15.

25

EXAMPLE 2

1-[3-[[4-[2-(1-Methylethoxy)phenyl]-1-piperazinyl]-1-oxide]methyl]benzoyl]piperidine 1.1Perchlorate 0.4Hydrate (Compound 2)

30 The third component to be isolated from the chromatography described in Example 1 was the title compound listed, 2.62 g, indicating a 3.4:1 preference for oxidation of the benzylic amine relative to the aniline nitrogen. This material was dissolved in MeOH (ca. 10 mL) and treated with 70% aqueous perchloric acid, and then triturated with ether, causing the
35 perchlorate salt of the title compound to emerge. Analysis of the H-1 NMR spectrum (400-MHz, CD₃OD) and mass spectrum of the compound confirmed the structure indicated. ¹H NMR (CD₃OD, 250 MHz) δ 7.65 (d, 1H), 7.6 (m, 3H), 7.0 (m, 3H), 6.9 (t, 1H), 4.95 (s, 2H), 4.65 (q, 1H), 4.0 (t, 2H), 3.7 (m, 4H), 3.6 (d, 2H), 3.35 (m, 4H), 1.7 (m, 4H), 1.55 (m, 1H), 1.35 (d, 6H).

Elemental Analysis: Calculated for $C_{26}H_{35}N_3O_3 \cdot 1.1HClO_4 \cdot 0.4H_2O$: C, 56.23; H, 6.65; N, 7.56; Cl, 7.02; H_2O , 1.29. Found: C, 56.01; H, 6.64; N, 7.08; Cl, 7.36; H_2O , 1.21.

5

EXAMPLE 3

1-[3-[[4-[2-(1-Methylethoxy)phenyl]-1-piperidinyl]-1-oxide]methyl]benzoyl]-
cis-2,6-dimethylpiperidine 0.6Hydrate 0.25Chloroform (Compound 3)

1 0 A mixture of 2-bromophenol (23.2 mL, 0.20 mol), potassium carbonate
(33.2 g, 0.24 mol) and 2-bromopropane (28.0 mL, 0.30 mol) in
dimethylformamide (200 mL) was stirred in a preheated oil bath (60°C) for 5
h. The cooled reaction mixture was then partitioned between ether and
water. The layers were separated and the aqueous phase was extracted
1 5 with ether. The combined organic solution was washed with copious
amounts of water, 3N aqueous NaOH, dried ($MgSO_4$), filtered and
concentrated in vacuo to furnish 39.3 g (91%) of 2-
(isopropoxy)bromobenzene as a pale yellow oil which was carried on
without further purification. The structure was supported by GC/MS and 90
MHz 1H NMR.

2 0

To a suspended solution of Mg chips (10.07 g, 0.414 mol) in anhydrous
ether (150 mL) at 22°C under argon was added ca. 0.15 mL of 1,2-
dibromoethane. Then 43.7 g (0.200 mol) of 2-(isopropoxy)bromobenzene in
200 mL of ether was added dropwise. After 50% of the aryl halide was
2 5 added, the reaction began to reflux vigorously. The flask was cooled in an
ice bath. After the refluxing had subsided somewhat, the ice bath was
removed and the remaining aryl halide was added over a 1.5 h period. The
resultant Grignard reagent was cooled in a dry ice/ether bath for 2 h and
then treated with 34.0 mL (0.221 mol) of 98% 1-carbethoxy-4-piperidone.
3 0 Upon complete addition of ketone, the reaction mixture was allowed to warm
to 22°C and stirred for 2 h. The reaction was then quenched with cold
aqueous ammonium chloride which resulted in an emulsion. Addition of 1M
aqueous HCl solution separated the two layers. The aqueous phase was
extracted with additional ether and the combined organic solution was
3 5 washed with 10% aqueous sodium bisulfite, 1.0 M HCl, saturated $NaHCO_3$,
and dried (K_2CO_3). Filtration and concentration yielded 56.36 g of 1-
carbethoxy-4-[2-(1-methylethoxy)phenyl]-4-piperidinol as a yellow viscous
oil which was carried on without further purification. The structure of this oil
was supported by 1H NMR.

A crude solution of 1-carbethoxy-4-[2-(1-methylethoxy)phenyl]-4-piperidinol (36 g), 10% palladium on carbon (1.80 g), 5 mL of concentrated HCl and 125 mL of MeOH was shaken on a Parr apparatus under 55.5 psig of hydrogen at 22°C for 3 d. The reaction was filtered over Celite, and concentrated to a residue. This material was partitioned between ether and water. The organic solution was dried (MgSO₄), filtered, and concentrated to yield 29.34 g of 1-carbethoxy-4-[2-(1-methylethoxy)phenyl]piperidine as a light yellow oil which was carried forward without further purification. The structure was supported by MS and ¹H NMR.

1 0

A mixture of crude 1-carbethoxy-4-[2-(1-methylethoxy)phenyl]piperidine (29.3 g) and sodium hydroxide pellets (6.12 g, 0.106 mol) in DMSO (100 mL) was stirred in a preheated oil bath at 100°C for 4 d. The reaction mixture was then poured into water (200 mL) and the crude product was extracted into methylene chloride. The methylene chloride extracts were dried over MgSO₄, filtered and concentrated to afford 21.34 g of a crude dark brown oil. This oil was dissolved in 1N aqueous HCl solution and washed with ether. The acidic aqueous solution was basified with 3N NaOH and the product was extracted into methylene chloride. The combined methylene chloride extracts were dried (MgSO₄), filtered and concentrated to yield 13.34 g of a semi-solid. This material was dissolved in iPrOH and acidified to a pH of 3 with concentrated HCl. The acidified solution was diluted with ether resulting in precipitation of the monohydrochloride salt which was collected by filtration and dried under vacuum to provide 11.21 g of 4-[2-(1-methylethoxy)phenyl]piperidine hydrochloride as a beige powder. The structure was supported by MS. The free base was obtained by extraction into CHCl₃ from 1N NaOH, drying (MgSO₄), and filtration.

In 100 ml of 2-pyridone, 4-(2-isopropoxyphenyl)piperidine (5.69 g, 0.0259 mol), 3-(chloromethyl)benzoyl-2,6-cis-dimethylpiperidine (6.91 g, 0.0259 mol), and sodium carbonate (8.75 g, .0825 mol) were combined and heated to 70°C. After 2.5 hours, the oil bath was removed and the reaction cooled to room temperature while stirring overnight. The crude reaction mixture was diluted with chloroform and then subjected to flash chromatography on silica with chloroform as eluant resulting in the isolation of slightly impure product (7.95 g; 68%). Conversion to its corresponding HCl salt, followed by neutralization provided pure free-base product. The assigned structure was supported by NMR and MS. Elemental Analysis




calculated for $C_{29}H_{40}N_2O_2 \cdot 0.25H_2O \cdot HCl$: C, 71.14; H, 8.54; N, 5.72; Cl, 7.24; H_2O , 0.92. Found: C, 71.20; H, 8.83; N, 5.59; Cl, 6.99; H_2O , 0.55.

5 A solution of *m*-chloroperoxybenzoic acid (0.80 g, 4.63 mmol) in $CHCl_3$ (10 mL) was added dropwise to a suspended mixture of 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperidiny]-1-oxide]methyl]benzoyl]-cis-2,6-dimethylpiperidine in $CHCl_3$ (10 mL) while stirring at 0°C. The reaction was continued overnight. The solvent was then removed and the residue was purified on a silica gel column ($CHCl_3/MeOH$, 100:0 to 90:10). The solid 10 which was obtained was recrystallized from $CHCl_3$ /hexane to give the title compound as a white powder (0.70 g), m.p. 104-106°C. 1H NMR (CD_3OD , 400 MHz) δ 7.7 (s, 1H), 7.58 (d, 1H), 7.53 (t, 1H), 7.45 and 7.35 (both d, 1H each), 7.14 (t, 1H), 6.95 (d, 1H), 6.9 (t, 1H), 4.6 (m, 1H), 4.45 (s, 2H), 3.5 (t, 2H), 3.2 (m, 2H), 2.4 (q, 2H), 1.93 (m, 1H), 1.7 15 (m, 10 H), and 1.3 (d, 6H). The mass spectra also supported the assigned structure.

Elemental Analysis calculated for $C_{29}H_{40}N_2O_3 \cdot H_2O \cdot CHCl_3$: C, 69.50; H, 8.20; N, 5.54; H_2O , 2.18. Found: C, 69.23; H, 8.36; N, 5.43; H_2O , 2.09.


20

TABLE 1

Structure	Compd. #	% CAR at 15 mg/kg (Loss of escape)	Dopamine-2 (nM)
	1	-91.7 (44.8)	140
	2	-87.6 (31.5)	355
	3	-37.7 (0.4)	371

WE CLAIM:

1. A compound represented by the formula I:



wherein

A is N, CH, or N⁺-O⁻;

- 10 B is N, or N⁺-O⁻; with the proviso that when A is N or CH, B must be N⁺-O⁻; and when A is N⁺-O⁻, B must be N.

W is C or SO;

- 15 R¹ and R² are H or C₁-C₄ alkyl.

n = 0-4;

- 20 R³ and R⁴ are either both H, or one of them is H and the other is C₁-C₄ alkyl or hydroxyl, or both are taken together as oxygen to constitute a carbonyl group, with the proviso that when n=0, R³ and R⁴ can not be taken together as oxygen.


- 25 R⁵ and R⁶ are independently selected from any one of H, C₁-C₈ alkyl, C₁-C₈ alkoxy, nitro, halogen, haloalkyl, C₁-C₈ alkylthio, amino, C₁-C₈ mono- or dialkyl amino, or C₁-C₈ alkylamido;

R⁷ is O or S where W is C; R⁷ is O where W is SO;

- 30 R⁸ and R⁹ are independently selected from any one of H, C₁-C₈ alkyl, C₁-C₈ aminoalkyl, phenyl, substituted phenyl, aralkyl wherein the alkyl portion is C₁-C₈, C₁-C₈ acyl, C₃ to C₁₀ cycloalkyl; or -NR⁸R⁹ may be taken together to form a ring having 4-10 ring atoms, which ring may be saturated or unsaturated, substituted or unsubstituted, and may contain

one or more hetero atoms in addition to the ring N, such as S, O or N within the ring; or optionally -NR⁸R⁹ may be combined with a 2-4 membered carbon moiety to form a fused bicyclic ring, which may be saturated or unsaturated, and unsubstituted or substituted; or optionally NR⁸R⁹ may be combined with a 4 membered moiety containing at least two carbon atoms and up to two hetero atoms selected from S or O, to form a spirocycle ring system; which may be saturated, or unsaturated, substituted or unsubstituted, or the acceptable acid addition salt, hydrate, solvate, isomers or racemates thereof.

2. The compound of claim 1, wherein when Ar is a fused ring system represented by the formula II:



wherein B together with the 2 carbon atoms of the phenyl group forms an entirely or partly unsaturated cyclic group having 5-7 ring atoms and within the ring 0-3 hetero atoms from any of O, S or N, with the proviso that the sum of the number of O and S atoms is at most 2, and that the N atoms in the ring may be substituted with R¹² selected from any one of H, alkyl, hydroxyalkyl or acyl;

wherein R¹⁰ and R¹¹ are independently selected from any one of alkyl, C₃-C₇ cycloalkyl, phenyl, substituted phenyl, heteroaryl, hydroxyalkyl, alkoxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, mono- or diarylamino, hydroxyl, amino, alkyl-, alkoxy-, amino-, mono- or dialkylamino-carbonyl, nitro, cyano, halogen, trifluoromethyl, trifluoromethoxy, amino-, or mono-, or dialkylamino-sulfonyl; R¹⁰ may also be oxo or thioxo; m is 0-3 and p is 0-2.

3. The compound of claim 2, wherein B forms together with the two carbon atoms of the phenyl group an entirely or partly unsaturated ring consisting of 5 ring atoms, at least one of which is an oxygen atom;

wherein R¹⁰ and R¹¹ are independently selected from any one of alkyl, alkoxy, hydroxyl, nitro, cyano, halogen, trifluoromethyl, with the proviso that R₆ is in the meta or ortho position in relation to the piperazine ring; wherein each of m and p has the value of 0-2.

5

4. The compound of claim 3, wherein m and p each equal 0.

10

5. The compound of claim 2, wherein when R¹⁰ or R¹¹ comprise an alkyl group and such group contains 1-5 carbon atoms and when R¹⁰ or R¹¹ comprise a cycloalkyl group the ring system that has 3-7 ring atoms and not more than 10 carbon atoms including substituents.

15

6. The compound of claim 1, wherein Ar is phenyl substituted with an alkoxy group; A is N; n is 0; and R¹, R², R³, and R⁴ is H.

20

7. The compound of claim 6, wherein the alkoxy group is i-propoxy.

8. The compound of claim 1, wherein R⁸R⁹ are taken together as -NR⁸R⁹ to form a ring having 4-8 ring atoms, which ring is saturated and contains up to one more hetero atom selected from any of N, O or S, in addition to the N.

25

9. The compound of claim 8, wherein the 4-8 membered ring is unsubstituted.



30


10. The compound of claim 8, wherein the 4-8 membered ring is substituted with one or more of C₁-C₈ alkyl, C₁-C₈ alkoxy, phenyl, substituted phenyl, hydroxy, aralkyl, oxo or thio, wherein phenyl may be substituted with one or more of C₁-C₈ alkyl, C₁-C₈ alkoxy, halogen, trifluoromethyl, C₁-C₈ alkyl, dialkylamino wherein each alkyl is C₁-C₈, C₁-C₈ alkylamino, nitro or mono- or dialkylamino sulfonyl wherein each alkyl is C₁-C₈.

35

11. The compound of claim 1, wherein the -NR⁸R⁹ 4-10 membered ring is saturated prior to being combined with the 2-4 membered carbon moiety to form a fused ring.

12. The compound of claim 1, wherein the 4 membered moiety used to form the spirocycle ring system contains 2 oxygen atoms separated by 2 carbon atoms.
- 5 13. The compound of claim 6, wherein W is C, wherein R⁵ is O and wherein each of R⁶ and R⁷ are H.
14. The compound of claim 6, wherein W is SO, wherein R⁵ is O and wherein each of R⁶ and R⁷ are H.
- 10 15. The compound of claim 6, wherein W is C, wherein R⁵ is S and wherein each of R⁶ and R⁷ is H.
16. The compound of claim 13, wherein -NR⁸R⁹ are taken together to form a saturated ring having 6 ring atoms.
- 15 17. The compound of claim 1, wherein Ar is substituted phenyl, and it is substituted with one or more of C₁-C₈ alkyl, C₁-C₈ alkoxy, cyano, C₁-C₈ alkylthio, halogen, haloalkyl, trifluoromethyl, amino, or mono- or di-alkylamino.
- 20 18. The compound of claim 12, wherein Ar is substituted with one or more of C₁-C₈ alkyl, C₁-C₈ alkoxy, halogen or haloalkyl and wherein -NR⁸R⁹ are taken together to form a saturated ring having 4-8 carbon ring atoms with the N being the only hetero atom in the ring.
- 25 19. A compound selected from any of:





- 5 wherein R^8 and R^9 are independently selected from any one of H, C_1 - C_8 alkyl, phenyl, substituted phenyl, C_6 - C_{15} aralkyl, C_1 - C_8 acyl, C_4 - C_{10} cycloalkyl; or $-NR^8R^9$ may be taken together to form a ring, substituted or unsubstituted having 4-10 ring atoms, which ring may be saturated or unsaturated, and may contain one or more hetero atoms selected
10 from S, O, N within the ring; or $-NR^8R^9$ may be taken together to form a spiro ring system, substituted or unsubstituted, which ring system may be saturated or unsaturated;

- 15 wherein R^{12} and R^{13} are selected from any one of H, C_1 - C_8 alkyl, C_1 - C_8 alkoxy, cyano, C_1 - C_8 alkylthio, halogen, haloalkyl, amino, or C_1 - C_8 mono- or dialkylamino, or the pharmaceutically acceptable acid addition salts, hydrates, solvates, isomers or racemates thereof.

20. The compound of claim 19 wherein R^{12} is C_1 - C_8 alkoxy.
20.
21. The compound of claim 20, wherein $-NR^8R^9$ are taken together to form a fully saturated ring containing 5 ring carbon atoms.
22. The compound of claim 21, wherein the NR^8R^9 ring is independently
25 substituted with any C_1 - C_8 alkyl.
23. The compound of claim 21, wherein the NR^8R^9 ring is unsubstituted.
24. The compound of claim 19 represented by the formula 1-[3-[[4-[2-(1-methylethoxy)phenyl]-4-oxide-1-piperazinyl]methyl]benzoyl]piperidine.
30
25. The compound of claim 19 represented by the formula 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl-1-oxide]methyl]benzoyl]piperidine.

26. The compound of claim 1 represented by the formula 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperidinyl-1-oxide]methyl]benzoyl]-cis-2,6-dimethylpiperidine.
- 5 27. A composition comprising the compound of claim 1, and a pharmaceutically acceptable carrier, said compound being present in a therapeutically effective amount.
- 10 28. A method for treating psychotic conditions in animals comprising administering to an animal in need of such treatment the compound of claim 1 in an amount sufficient to treat such condition.
29. The method of claim 26, wherein the condition is schizophrenia.
- 15 30. The method of claim 26, wherein Ar is phenyl substituted with a C₁-C₈ alkoxy.
31. The compound of claim 27, wherein the NR⁸R⁹ ring is independently substituted with any of C₁-C₈ alkyl.
- 20 32. The compound of claim 27, wherein the NR⁸R⁹ ring is unsubstituted.
33. The method of claim 28, wherein -NR⁸R⁹ are taken together with the N to form a fully saturated ring containing 5 carbon atoms.
- 25 34. The method of claim 27, represented by the formula 1-[3-[[4-[2-(1-methylethoxy)phenyl]-4-oxide-1-piperazinyl]methyl]benzoyl]piperidine.
- 30 35. The method of claim 27, represented by the formula 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl-1-oxide]methyl]benzoyl]piperidine.
- 35 36. The method of claim 27, represented by the formula 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperidinyl-1-oxide]methyl]benzoyl]-cis-2,6-dimethylpiperidine.

INTERNATIONAL SEARCH REPORT

Int. onal Application No
PCT/US 94/14850

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07D211/94 C07D295/22 A61K31/445		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,93 04682 (MCNEILAB) 18 March 1993 cited in the application see the whole document ---	1-36
Y	XENOBIOTICA, vol.23, no.5, 1993 pages 495 - 508 GORROD, FANG 'On the metabolism of haloperidol' see page 102, line 4 - line 7 ---	1-36
P,A	FR,A,2 697 251 (SYNTHELABO) 29 April 1994 see the whole document -----	1-36
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents :</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*&* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">13 April 1995</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">27. 04. 95</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+ 31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Kissler, B</div>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 94/14850

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9304682	18-03-93	AU-A- 1363392	05-04-93
		AU-B- 657799	23-03-95
		AU-A- 2659992	05-04-93
		CA-A- 2095826	12-03-93
		CA-A- 2095847	12-03-93
		EP-A- 0562049	29-09-93
		EP-A- 0563345	06-10-93
		FI-A- 932103	10-05-93
		FI-A- 932104	10-05-93
		HU-A- 64535	28-01-94
		JP-T- 6502870	31-03-94
		JP-T- 6502183	10-03-94
		WO-A- 9304684	18-03-93

FR-A-2697251	29-04-94	NONE	
